SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Theraclone Sciences, Inc. Presents Phase 1 Results of TCN-032, Its Therapeutic Antibody Directed at Influenza A, at ICAAC 2012